Report period | 2017 | 2018 | 2019 | 2020 | 2021 | Q2 22 |
---|---|---|---|---|---|---|
End date of the reporting period | ||||||
Capitalization, $ | ||||||
Capitalization, $ | ||||||
Enterprise Value | ||||||
Book Value | ||||||
Shareholders Book Value | ||||||
Current liabilities | ||||||
Noncurrent liabilities | ||||||
Total liabilities | ||||||
Debt | ||||||
Cash and cash equivalents | ||||||
Net debt | ||||||
Assets | ||||||
Total ordinary shares | ||||||
Ordinary share price |
Ticker | Name | Type | Nominal value | ISIN | Price |
---|---|---|---|---|---|
NNVC:US | NanoViricides | Common share | - | US6300873022 | $1.49 |
Company name | NanoViricides |
---|---|
Tags | #biotechnology, #vaccines |
Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
Business address | 1 Controls Drive Shelton, CT 06484 United States |
Mailing address | 1 Controls Drive Shelton, CT 06484 United States |
Website | www.nanoviricides.com |
Information disclosure | www.sec.gov |